[Predictors for the Bronchiolitis Obliterans Syndrome in Lung Transplant Patient].

Lung transplantation is the ultimate treatment of end-stage lung disease. After transplantation, the 1-year survival rate is 80%, while the 5-year survival rates remaines at around 50% mainly due to bronchiolitis obliterans syndrome (BOS). BOS is regarded as a fibrosing process in the small airways leading to irreversible airway obstruction. A lot of factors are involved in the development of BOS, such as Ischemia/reperfusion injury, infections, oxidative stress, and acute rejection, etc. Studies have shown that early diagnosis of BOS may improve outcome. It is valuable for the long-term survival of lung transplantation to find out several predictors for the BOS. This article reviews the current state of knowledge on predictors for BOS.

[1]  A. Koutsokera,et al.  Blood Gene Expression Predicts Bronchiolitis Obliterans Syndrome , 2018, Front. Immunol..

[2]  F. Meloni,et al.  1H NMR To Evaluate the Metabolome of Bronchoalveolar Lavage Fluid (BALf) in Bronchiolitis Obliterans Syndrome (BOS): Toward the Development of a New Approach for Biomarker Identification. , 2017, Journal of proteome research.

[3]  Philip R. Gafken,et al.  Proteomic Characterization Reveals That MMP‐3 Correlates With Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Cell and Lung Transplantation , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  R. Elashoff,et al.  The Role of TGF‐β in the Association Between Primary Graft Dysfunction and Bronchiolitis Obliterans Syndrome , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  L. Voltolini,et al.  Exhaled nitric oxide and carbon monoxide in lung transplanted patients. , 2015, Respiratory medicine.

[6]  T. Martinussen,et al.  The number of FoxP3+ cells in transbronchial lung allograft biopsies does not predict bronchiolitis obliterans syndrome within the first five years after transplantation , 2015, Clinical transplantation.

[7]  G. Verleden,et al.  Differential Cytokine, Chemokine and Growth Factor Expression in Phenotypes of Chronic Lung Allograft Dysfunction , 2015, Transplantation.

[8]  S. Bhorade,et al.  Association of Soluble HLA-G with Acute Rejection Episodes and Early Development of Bronchiolitis Obliterans in Lung Transplantation , 2014, PloS one.

[9]  P. Jaksch,et al.  Pretransplant serum human chitinase-like glycoprotein YKL-40 concentrations independently predict bronchiolitis obliterans development in lung transplant recipients. , 2014, The Journal of thoracic and cardiovascular surgery.

[10]  Jeffrey L. Curtis,et al.  Changes in the Lung Microbiome following Lung Transplantation Include the Emergence of Two Distinct Pseudomonas Species with Distinct Clinical Associations , 2014, PloS one.

[11]  W. Bian,et al.  KL-6 regulated the expression of HGF, collagen and myofibroblast differentiation. , 2013, European review for medical and pharmacological sciences.

[12]  S. Hodge,et al.  Up‐regulation of alternate co‐stimulatory molecules on proinflammatory CD28null T cells in bronchiolitis obliterans syndrome , 2013, Clinical and experimental immunology.

[13]  W. Wallace,et al.  Bronchiolitis Obliterans Syndrome: The Achilles' Heel of Lung Transplantation , 2013, Seminars in Respiratory and Critical Care Medicine.

[14]  S. Yerkovich,et al.  Mesenchymal stem cells and the lung , 2013, Respirology.

[15]  A. G. Arroyo,et al.  Site-specific cellular functions of MT1-MMP. , 2012, European journal of cell biology.

[16]  S. Keshavjee,et al.  Regression of allograft airway fibrosis: the role of MMP-dependent tissue remodeling in obliterative bronchiolitis after lung transplantation. , 2011, The American journal of pathology.

[17]  S. Palmer,et al.  Bronchiolitis obliterans syndrome: the final frontier for lung transplantation. , 2011, Chest.

[18]  C. Larsen,et al.  Regulatory T cells in lung transplantation—an emerging concept , 2011, Seminars in Immunopathology.

[19]  J. Belperio,et al.  Lung transplantation: infection, inflammation, and the microbiome , 2011, Seminars in Immunopathology.

[20]  P. Jaksch,et al.  Endothelin-1 is a useful biomarker for early detection of bronchiolitis obliterans in lung transplant recipients. , 2010, The Journal of thoracic and cardiovascular surgery.

[21]  E. Smith,et al.  Serum KL‐6 level and the development of bronchiolitis obliterans syndrome in lung transplant recipients , 2010, Pediatric transplantation.

[22]  D. Rockey,et al.  Endothelin--biology and disease. , 2010, Cellular signalling.

[23]  A. Lindén,et al.  Increased net gelatinase but not serine protease activity in bronchiolitis obliterans syndrome. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[24]  W. Wallace,et al.  Chronic Allograft Rejection: Epidemiology, Diagnosis, Pathogenesis, and Treatment , 2010, Seminars in respiratory and critical care medicine.

[25]  G. Heinze,et al.  Concomitant Endothelin‐1 Overexpression in Lung Transplant Donors and Recipients Predicts Primary Graft Dysfunction , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  M. Fishbein,et al.  Chronic lung allograft rejection: mechanisms and therapy. , 2009, Proceedings of the American Thoracic Society.

[27]  H. Otten,et al.  Soluble CD30 measured after lung transplantation does not predict bronchiolitis obliterans syndrome in a tacrolimus/mycophenolate mofetil-based immunosuppressive regimen. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[28]  E. Trulock,et al.  Soluble CD30 levels as a diagnostic marker for bronchiolitis obliterans syndrome following human lung transplantation. , 2008, Transplant immunology.

[29]  R. Bag,et al.  Serum KL-6 as a marker for bronchiolitis obliterans syndrome after lung transplantation. , 2006, Transplantation.

[30]  H. Otten,et al.  Pre-transplant soluble CD30 is associated with bronchiolitis obliterans syndrome after lung transplantation. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[31]  P. Jaksch,et al.  Broncho‐alveolar Lavage Matrix Metalloproteases as a Sensitive Measure of Bronchiolitis Obliterans , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[32]  T. Pufe,et al.  Matrix metalloproteinase-9 in bronchiolitis obliterans syndrome after lung transplantation , 2005, European Respiratory Journal.

[33]  E. Brambilla,et al.  Alveolar neutrophilia is a predictor for the bronchiolitis obliterans syndrome, and increases with degree of severity. , 2002, Transplant immunology.

[34]  P. Bongrand,et al.  Upregulation of chemokines in bronchoalveolar lavage fluid as a predictive marker of post-transplant airway obliteration. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[35]  W. Ryd,et al.  Persistent high BAL fluid granulocyte activation marker levels as early indicators of bronchiolitis obliterans after lung transplant. , 1999, The European respiratory journal.

[36]  F. Kelly,et al.  Bronchiolitis obliterans syndrome in lung transplant recipients is associated with increased neutrophil activity and decreased antioxidant status in the lung. , 1998, The European respiratory journal.

[37]  F. Martinez,et al.  Bronchoalveolar lavage neutrophilia is associated with obliterative bronchiolitis after lung transplantation: role of IL-8. , 1996, Journal of immunology.